Keep a water bottle accessible and aim to consume fluids before you feel thirsty
They are a great alternative to the abdomen and are essential for any good site rotation schedule

Flow cytometry and cell sorting For analysis of spinal cord cell populations, stainings were performed in PBS using fixable viability dye (Invitrogen, 65-0865-14, 1:2,000, 10 min at room temperature) as well as the following antibodies: CD45.2-BV650 (clone 104, Biolegend, 109836, 1:100), Ly6G-BV605 (clone 1A8, Biolegend, 127639, 1:100), Ly6G-AF700 (clone 1A8, Biolegend, 127622, 1:100), CD3-BV605 (clone 145-2C11, Biolegend, 100351, 1:100), Ly6C-BV605 (clone HK14, Biolegend, 128035, 1:100), Ly6C-BV510 (clone HK14, Biolegend, 128033, 1:100), CD11b-BV510 (clone M1/70, Biolegend, 101245, 1:100), CD11b-PB (clone M1/70.15, Invitrogen, RM2828, 1:100), CD11b-BV605 (clone M1/70, Biolegend, 101237, 1:100), CX3CR1-PeCy7 (clone SA011F11, Biolegend, 149015, 1:100), CCR2-BV421 (clone SA203G11, Biolegend, 150605, 1:100), CCR2-FITC (clone SA203G11, Biolegend, 150607, 1:100), F4/80-BV510 (clone BM8, Biolegend, 123135, 1:100), F4/80-BV605 (clone BM8, Biolegend, 123133, 1:100), F4/80-FITC (clone BM8, Biolegend, 123108, 1:100), CD11c-PE-Cy5.5 (clone N418, Invitrogen, 35-0114-82, 1:100), P2RY12-APC (clone S16007D, Biolegend, 848006, 1:100), P2RY12-AF488 (clone S16007D, Biolegend, 848016, 1:100), MerTK-APC (clone 2B10C42, Biolegend, 151507, 1:100), CD44-FITC (clone IM7, Invitrogen, 11-0441-82, 1:100), CD44-eF506 (clone IM7, Invitrogen, 69-0441-82, 1:100), CD64-BV605 (clone X54-5/7.1, Biolegend, 139323, 1:100), CD3-AF700 (clone 17A2, Biolegend, 100216, 1:100), CD3-rF710 (clone 17A2, Tonbo, 80-0032-U100, 1:80), CD8-BV510 (clone 53-6.7, Biolegend, 100751, 1:80), CD4-APC (clone REA604, Miltenyi Biotec, 130-116-487, 1:80), CD4-PE (clone REA604, Miltenyi Biotec, 130-116-509, 1:80) and CD25-BV421 (clone PC61, Biolegend, 102033, 1:80)

Alzheimers Dement 10 , S26S32 (2014)
Homocysteine in Neurology: A Possible Contributing Factor to Small Vessel Disease. International Journal of Molecular Sciences, vol
This review highlights recent progress in metallic nanostructure-mediated PTT, underlying mechanisms, and future challenges, underscoring its promise as a cornerstone in personalized management of metastatic cancers